Skip to main content

Table 3 Prognostic evaluation of clinicopathological parameters for cancer-specific survival in 36 cases of metastatic renal cell carcinomas by univariate and multivariate analyses

From: A risk stratification model based on four novel biomarkers predicts prognosis for patients with renal cell carcinoma

   Univariate Multivariate
  n HR
(95% CI)
p value† HR
(95% CI)
p value†
Sex
(male/female)
30/6 2.56
(0.68–9.76)
0.164   
Age, years
(> 62 vs ≤ 62)
18/18 0.52
(0.17–1.57)
0.247   
Histological subtype
(non-clear vs clear)
5/31 0.65
(0.08–5.25)
0.652   
T classification
(3,4 vs 1,2)
20/16 2.83
(0.89–9.00)
0.077   
Vascular invasion
(yes vs no)
34/2 25.44
(0.02–44141)
0.395   
Pathological grade
(3 vs 1,2)
13/23 4.82
(1.36–17.06)
0.015 1.24
(0.25–6.17)
0.792
Metastasis at diagnosis
(yes vs no)
27/9 5.41
(1.16–25.26)
0.032 6.26
(1.19–33.00)
0.031
Molecular targeting therapy (yes vs no) 25/11 1.33
(0.44–4.00)
0.617   
ARL4C expression
(high vs low)
15/21 4.20
(1.39–12.72)
0.011 2.37
(0.52–10.51)
0.273
ECT2 expression
(high vs low)
15/21 2.85
(0.87–9.34)
0.084   
SOD2 expression
(high vs low)
12/24 4.07
(1.28–12.94)
0.018 4.97
(1.12–22.02)
0.035
STEAP3 expression
(high vs low)
8/28 5.16
(1.56–17.08)
0.007 2.19
(0.45–9.970)
0.343
  1. †Cox proportional hazards regression models
  2. HR hazard ratio, CI confidence interval